Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM6A7P)

• Drug Name: cannabinol Drug Info
• Synonyms: cannabinol; 521-35-7; Cannabinolo [DCIT]; Cannabinolum [INN-Latin]; Cannabinol [INN:BAN]; UNII-7UYP6MC9GH; 6H-Dibenzo(b,d)pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; NSC 134455; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo(b,d)pyran; 7UYP6MC9GH; BRN 0237145; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; CHEMBL74415; CHEBI:3360; VBGLYOIFKLUMQG-UHFFFAOYSA-N; 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2543
  ChEBI ID: CHEMBL74415
  CAS Number: CAS 521-35-7
  TTD Drug ID: DMM6A7P

Molecule-Related Drug Atlas

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[5]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[6]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[7]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[8]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[9]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[10]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[11]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[12]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[13]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[14]

Drug(s) Targeting Transient receptor potential cation channel V2 (TRPV2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[15]
2-APB	DM9AKVR	Discovery agent	N.A.	Investigative	[15]
lysophosphatidylcholine	DMOGFVH	Discovery agent	N.A.	Investigative	[16]
diphenylboronic anhydride	DMRQZTS	Discovery agent	N.A.	Investigative	[15]
lysophosphatidylinositol	DMETM3R	Discovery agent	N.A.	Investigative	[16]
citral	DM53ZGY	Discovery agent	N.A.	Investigative	[17]
TRIM	DMNHU4M	Discovery agent	N.A.	Investigative	[15]

Drug(s) Affected By Transient receptor potential cation channel subfamily A member 1 (TRPA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[20]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[21]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[22]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[19]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[23]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[24]
phorbol 12-myristate 13-acetate	DMJWD62	Acute myeloid leukaemia	2A60	Phase 2	[25]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Agonist	[2]
Transient receptor potential cation channel V2 (TRPV2)	TTBECWA	TRPV2_HUMAN	Activator	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Transient receptor potential cation channel subfamily A member 1 (TRPA1)	OTRDIR5M	TRPA1_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 740).
• [2] Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996 Sep;278(3):989-99.
• [3] TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008 Jun 11;28(24):6231-8.
• [4] Diverse TRPV1 responses to cannabinoids. Channels (Austin). 2019 Dec;13(1):172-191. doi: 10.1080/19336950.2019.1619436.
• [5] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [6] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [7] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [8] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [9] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [10] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [11] Company report (Gwpharm)
• [12] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [13] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [14] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [15] Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68.
• [16] Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39.
• [17] Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082.
• [18] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [19] Electrophilic components of diesel exhaust particles (DEP) activate transient receptor potential ankyrin-1 (TRPA1): a probable mechanism of acute pulmonary toxicity for DEP. Chem Res Toxicol. 2011 Jun 20;24(6):950-9. doi: 10.1021/tx200123z. Epub 2011 May 25.
• [20] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [21] The anthelminthic drug praziquantel is a selective agonist of the sensory transient receptor potential melastatin type 8 channel. Toxicol Appl Pharmacol. 2017 Dec 1;336:55-65. doi: 10.1016/j.taap.2017.10.012. Epub 2017 Oct 18.
• [22] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [23] Activation of the human TRPA1 channel by different alkylating sulfur and nitrogen mustards and structurally related chemotherapeutic drugs. Toxicol Lett. 2023 Mar 1;376:51-59. doi: 10.1016/j.toxlet.2023.01.007. Epub 2023 Jan 21.
• [24] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [25] Mechanisms and Consequences of Variable TRPA1 Expression by Airway Epithelial Cells: Effects of TRPV1 Genotype and Environmental Agonists on Cellular Responses to Pollutants in Vitro and Asthma. Environ Health Perspect. 2023 Feb;131(2):27009. doi: 10.1289/EHP11076. Epub 2023 Feb 27.
• [26] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.